Precigen to Announce Q1 2024 Financial Results on May 14 and Host Call on June 3 Post-PRGN-2012 ASCO Presentation

GERMANTOWN, Md., May 8, 2024 — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company that focuses on innovative gene and cell therapies, has scheduled the release of its first quarter 2024 financial results for Tuesday, May 14, 2024, after the market closes. Unlike typical practice, the company will not conduct a conference call to discuss these financial results.

Instead, Precigen has planned a conference call for Monday, June 3, 2024. During this call, the company will provide an in-depth discussion on the pivotal Phase 2 study data of PRGN-2012, a treatment aimed at recurrent respiratory papillomatosis (RRP). This data will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Further details about the June 3rd conference call will be shared closer to the date.

Precigen is committed to advancing medical treatments through precision technology to tackle serious and challenging diseases in key therapeutic areas such as immuno-oncology, autoimmune disorders, and infectious diseases. The company prides itself on its ability to innovate and deliver affordable biotherapeutics in a controlled manner, steadily progressing its preclinical and clinical pipelines toward clinical validation and eventual commercialization.

The company's approach emphasizes the utilization of precise gene and cell therapies to develop next-generation treatments. Precigen leverages its core technologies to discover solutions that address the needs of various critical health conditions. Their efforts are geared towards developing well-differentiated therapies that can offer meaningful benefits to patients.

The press release also included a cautionary statement regarding forward-looking statements. These statements, based on the company’s current expectations and projections, touch upon future events and the company's plans, objectives, and goals. They include expectations about the development and commercialization of product candidates, progress in clinical and preclinical studies, and the promise of Precigen’s therapy portfolio, especially its CAR-T and AdenoVerse therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!